Variant · Snv

PIK3CA Q546K

CI-VAR-00003547Explore in graph →NP_006209.2:p.Gln546LysNM_006218.3:c.1636C>AClinVar 13657 CIViC 885 rs121913286

Curated evidence

Evidence by cancer (5 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–5 of 5 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
PIK3CA Q546K	PI103	Predictive	D	Supports Sensitivity Response	—	submitted	EID2079 In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC) PMID 19513541 · Zou et al., 2009 · Open in CIViC	civic
Malignant Breast Neoplasm1
PIK3CA Q546K OR PIK3CA Q546E OR PIK3CA Q546P OR PIK3CA Q546R OR PIK3CA Q546L OR PIK3CA K111E OR PIK3CA K111N OR PIK3CA K111R OR PIK3CA Q546H	Fulvestrant + Inavolisib + PalbociclibCombination	Predictive	A	Supports Sensitivity Response	3	accepted

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
13657	Pathogenic	criteria provided, multiple submitters, no conflicts	2	OVARIAN CANCER, EPITHELIAL, SOMATIC; Carcinoma of colon; PIK3CA related overgrowth syndrome; Prostate cancer; Ovarian neoplasm; Segmental undergrowth associated with mainly venous malformation with capillary component; Megalencephaly-capillary malformation-polymicrogyria syndrome; Diffuse glioma, H3 G34 mutant; Medulloblastoma WNT activated; Diffuse midline glioma, H3 K27M-mutant; Neoplasm

Malignant Colorectal Neoplasm2
PIK3CA Q546K	Cetuximab	Predictive	C	Supports Resistance	—	rejected	EID3727 In a retrospective study of 168 chemotherapy-refractory metastatic colorectal cancer patients, patients with a PIK3CA mutation (n=26) treated with cetuximab in combination with standard chemotherapy, … (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
PIK3CA Q546K	Cetuximab + IrinotecanCombination	Predictive	C	Does Not Support Resistance	2	accepted	EID2198 One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA Q546K (exon 10), was wildtype for KRAS, BR… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic

Malignant Colorectal Neoplasm2

PIK3CA Q546K

Cetuximab

Predictive

Supports Resistance

—

rejected

EID3727

In a retrospective study of 168 chemotherapy-refractory metastatic colorectal cancer patients, patients with a PIK3CA mutation (n=26) treated with cetuximab in combination with standard chemotherapy, … (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

civic

PIK3CA Q546K

Cetuximab + IrinotecanCombination

Predictive

Does Not Support Resistance

accepted

EID2198

One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA Q546K (exon 10), was wildtype for KRAS, BR… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

civic

HER2 Negative Breast Cancer1unmapped disease
PIK3CA Q546K	Capivasertib + FulvestrantCombination	Predictive	A	Supports Sensitivity Response	2	submitted	EID12191 In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC	civic

HER2 Negative Breast Cancer1unmapped disease

PIK3CA Q546K

Capivasertib + FulvestrantCombination

Predictive

Supports Sensitivity Response

submitted

EID12191

In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC)

PMID 37256976 · Turner et al., 2023 · Open in CIViC

civic